News

The Wall Street Journal: FDA may OK COVID boosters for 16- and 17-year-olds as soon as next week

0

The Food and Drug Administration could authorize COVID-19 boosters from Pfizer Inc.
PFE,
-2.96%

 and BioNTech SE
BNTX,
+4.17%

 for use in 16- and 17-year-olds as soon as next week as concerns rise over a new, possibly more transmissible variant, according to a person familiar with the planning.

The agency is planning to move rapidly to take action on a request by the companies to authorize boosters for 16- and-17-year-olds, according to a person familiar with the matter. So far, only people 18 years and older are eligible for boosters.

Pressure has been mounting on the Biden administration to authorize boosters, especially in light of the emergence of omicron, a new variant with a worrying constellation of mutations that could reduce the efficacy of vaccines.

Vaccine makers have begun racing to assess whether their shots work as well against omicron as against other variants, or whether they will need to modify the doses to target the new strain.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Ghost kitchens are proving to be a messy business, as Reef Global shows.

Workers quit jobs in droves to become their own bosses.

Market Extra: S&P 500 may end ‘pretty flat’ in 2022 amid previously ‘unthinkable’ negative real rates, says BofA strategist

Previous article

Dow Jones Newswires: China manufacturing gauge shows surprise rebound in November

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News